Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia Public Deposited

http://ir.library.oregonstate.edu/concern/articles/f4752j47p

This is the publisher’s final pdf. The published article is copyrighted by the author(s) and co-published by Springer and Adis. The published article can be found at:  http://link.springer.com/journal/40265

Descriptions

Attribute NameValues
Creator
Abstract or Summary
  • Homozygous familial hypercholesterolemia (HoFH) is a rare, genetic disorder characterized by an absence or impairment of low-density lipoprotein receptor (LDLR) function resulting in significantly elevated low-density lipoprotein cholesterol (LDL-C) levels. The cholesterol exposure burden beginning in utero greatly increases the risk for atherosclerotic cardiovascular disease (ASCVD) and premature death. The genetic heterogeneity of HoFH results in a wide range of LDL-C levels among both untreated and treated patients. Diagnosis of HoFH should, therefore, be based on a comprehensive evaluation of clinical criteria and not exclusively LDL-C levels. As treatment goals, the European Atherosclerosis Society and International FH Foundation suggest target LDL-C levels of <100 mg/dL (<2.5 mmol/L) in adults or <70 mg/dL (<1.8 mmol/L) in adults with clinical coronary artery disease or diabetes. The National Lipid Association (NLA) recommends that LDL-C levels be reduced to <100 mg/dL (<2.5 mmol/L) or by at least ≥ 50 % from pretreatment levels. Conventional therapy combinations that lower atherogenic lipoproteins levels in the blood, such as statins, ezetimibe, bile acid sequestrants and niacin, as well as lipoprotein apheresis, are usually unable to reduce LDL-C levels to recommended targets. Two recently approved agents that reduce lipoprotein synthesis and secretion by the liver are lomitapide, a microsomal triglyceride transfer protein inhibitor, and mipomersen, an apolipoprotein B antisense oligonucleotide. The newly approved inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), evolocumab, also shows promise for the management of FH. Because of the extremely high risk for ASCVD, HoFH patients should be identified early.
Resource Type
DOI
Date Available
Date Issued
Citation
  • Ito, M. K., & Watts, G. F. (2015). Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia. Drugs, 75(15), 1715-1724. doi:10.1007/s40265-015-0466-y
Series
Rights Statement
Funding Statement (additional comments about funding)
Publisher
Peer Reviewed
Language
Replaces
Additional Information
  • description.provenance : Approved for entry into archive by Patricia Black(patricia.black@oregonstate.edu) on 2015-11-30T17:01:35Z (GMT) No. of bitstreams: 1 ItoMatthewPharmacyChallengesDiagnosisTreatment.pdf: 1007622 bytes, checksum: 0a458e74de3c627fa6bc84aa00006ca2 (MD5)
  • description.provenance : Submitted by Patricia Black (patricia.black@oregonstate.edu) on 2015-11-30T17:01:02Z No. of bitstreams: 1 ItoMatthewPharmacyChallengesDiagnosisTreatment.pdf: 1007622 bytes, checksum: 0a458e74de3c627fa6bc84aa00006ca2 (MD5)
  • description.provenance : Made available in DSpace on 2015-11-30T17:01:35Z (GMT). No. of bitstreams: 1 ItoMatthewPharmacyChallengesDiagnosisTreatment.pdf: 1007622 bytes, checksum: 0a458e74de3c627fa6bc84aa00006ca2 (MD5) Previous issue date: 2015-10

Relationships

Parents:

This work has no parents.

Last modified

Downloadable Content

Download PDF

Items